Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients

Biomarkers in Medicine

Volumn 4, Issue 5, 2010, Pages 755-759

  Arababadi, Mohammad Kazemi ^a   Mosavi, Reza ^a   Khorramdelazad, Hossein ^a   Yaghini, Narges ^a   Zarandi, Ebrahim Rezazadeh ^a   Araste, Majid ^b   Pourali, Reza ^c   Nekhei, Zohre ^b   Kennedy, Derek ^d  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Avonex ; Betaferon ; CinnoVex ; cytokine; multiple sclerosis; Rebif

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CINNOVEX; CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

ADULT; CYTOKINES; FEMALE; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-17; IRAN; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOMBINANT PROTEINS;

EID: 77958071334     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.81     Document Type: Article

References (21)

1. Ascherio A, Munger KL, Simon KC: Vitamin D and multiple sclerosis. Lancet Neurol. 9(6), 599-612 (2010).
2. Teunissen CE, Killestein J, Giovannoni G: Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomark. Med. 1(1), 111-119 (2007).
3. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell 140(6), 918-934 (2010).
4. Hillert J: The genetics of multiple sclerosis. Results Probl. Cell Differ. (2009) (Epub ahead of print).
5. Welsh CJ, Steelman AJ, Mi W et al.: Neuroimmune interactions in a model of multiple sclerosis. Ann. NY Acad. Sci. 1153, 209-219 (2009).
6. Subileau EA, Rezaie P, Davies HA et al.: Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 68(3), 227-240 (2009).
7. Carrieri PB, Ladogana P, Di Spigna G et al.: Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-b1a: differences in responders and non responders. Immunopharmacol. Immunotoxicol. 30(4), 1-9 (2008).
8. Dressel A, Kolb AK, Elitok E et al.: Interferon-b1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurol. Scand. 114(6), 368-373 (2006).
9. Etemadifar M, Janghorbani M, Shaygannejad V: Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing- remitting multiple sclerosis. Acta Neurol. Scand. 113(5), 283-287 (2006).
10. Khoei NS, Atashpaz S, Ghabili K, Khoei NS, Omidi Y: Melittin and hyaluronidase compound derived from bee venom for the treatment of multiple sclerosis. Irn J. Med Hypotheses Ideas 3(24), 1-5 (2009).
11. Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A: Treatment of early onset multiple sclerosis with suboptimal dose of interferon b-1a. Neuropediatrics 37(4), 257-260 (2006).
12. Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S: Diffusion of interferon-b in Iran and its utilization in Tehran. Pharmacoepidemiol. Drug Saf. 17(9), 934-941 (2008).
13. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B: Pharmacodynamic comparison of single doses of IFN-b1 and IFN-b1b in healthy volunteers. J. Interferon Cytokine Res. 19(11), 1257-1264 (1999).
14. Lunemann JD, Aktas O, Gniadek P, Zschenderlein R, Zipp F: Downregulation of transforming growth factor-b1 in interferon-b1-treated MS patients. Neurology 57(6), 1132-1134 (2001).
15. Losy J, Michalowska-Wender G: In vivo effect of interferon-b1a on interleukin-12 and TGF-b1 cytokines in patients with relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 106(1), 44-46 (2002).
16. McDonald WI, Compston A, Edan G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50(1), 121-127 (2001).
17. Lock C, Hermans G, Pedotti R et al.: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8(5), 500-508 (2002).
18. Bever CT Jr, Panitch HS, Levy HB, McFarlin DE, Johnson KP: g-interferon induction in patients with chronic progressive MS. Neurology 41(7), 1124-1127 (1991).
19. Szczuciñski A, Losy J: Long-term effect of IFN-b1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis. Folia Neuropathol. 42(1), 15-18 (2004).
20. Waubant E, Gee L, Miller K, Stabler G, Goodkin D: IFN-b1 may increase serum levels of TIMP-1 in patients with relapsing- remitting multiple sclerosis. J. Interferon Cytokine Res. 21(3), 181-185 (2001).
21. Losy J, Michalowska-Wender G, Wender M: [Chemokines MIP-1 and MCP-1 and patients with multiple sclerosis treated with interferon b-1a]. Neurol. Neurochir. Pol. 35(4), 583-588 (2001).